What is the latest MANKIND stock price?
The latest stored price for MANKIND is Rs 2,300.70 as of 2026-09-18.
gimli
MANKIND stock AI analysis
MANKIND Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MANKIND PHARMA LIMITED is a mid-cap stock in Healthcare. This Gimli page shows the latest available MANKIND price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹2,300.70
1W return
+2.78%
1M return
-3.33%
3M return
-4.38%
6M return
+9.40%
1Y return
-12.80%
Market cap
₹94,979.41 cr
PE
46.30
PB
5.74
ROE
+13.18%
ROCE
+10.21%
RSI
43.18
Turnover
₹111.48 cr
Why it can matter in screens
- Momentum: MANKIND is below 50DMA, above 200DMA; RSI is 43.18.
- Returns: 1D +0.03%, 1W +2.78%, 1M -3.33%, 3M -4.38%, 1Y -12.80%.
- Trend levels: 52W high ₹2,642.00, 52W low ₹2,222.00, off high -12.92%.
- Liquidity: latest turnover is ₹111.48 cr; volume vs 20D is +1.48%.
- Valuation/profitability: PE 46.30, PB 5.74, ROE +13.18%, ROCE +10.21%.
- Growth: 3Y sales CAGR +17.73%, 3Y profit CAGR +14.27%.
Quick Answers
Is MANKIND above its 50DMA and 200DMA?
MANKIND is below 50DMA, above 200DMA. The latest 50DMA is 2,426.34 and the latest 200DMA is 2,281.97.
What are MANKIND PE, ROE and ROCE?
MANKIND has PE 46.30, ROE +13.18%, and ROCE +10.21% in Gimli's latest available snapshot.
How has MANKIND performed recently?
MANKIND has returned -3.33% over 1 month, -4.38% over 3 months, and -12.80% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 4,030.59 cr | 1,105.13 cr | 568.06 cr | 13.76 |
| 2026-03-31 | 3,442.93 cr | 1,024.00 cr | 554.35 cr | 13.44 |
| 2025-12-31 | 3,567.20 cr | 888.80 cr | 408.75 cr | 9.90 |
| 2025-09-30 | 3,789.00 cr | 1,013.00 cr | 520.18 cr | 12.38 |
| 2025-06-30 | 3,570.35 cr | 929.82 cr | 438.32 cr | 10.62 |
| 2025-03-31 | 3,079.37 cr | 936.84 cr | 420.77 cr | 10.20 |
| 2024-12-31 | 3,198.79 cr | 896.43 cr | 380.23 cr | 9.45 |
| 2024-09-30 | 3,061.43 cr | 958.82 cr | 653.47 cr | 16.31 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 14,277.64 cr | 3,858.14 cr | 1,912.93 cr | 49.30 |
| 2025-03-31 | 12,207.44 cr | 3,566.96 cr | 1,990.96 cr | 49.28 |
| 2024-03-31 | 10,259.29 cr | 2,824.01 cr | 1,912.90 cr | 47.75 |
| 2023-03-31 | 8,749.43 cr | 2,037.43 cr | 1,281.86 cr | 32.00 |
| 2022-03-31 | 7,690.04 cr | 2,197.00 cr | 1,389.42 cr | 35.78 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 28,079.53 cr | 391.69 cr | 6,311.54 cr | 16,561.05 cr |
| 2025-03-31 | 27,759.53 cr | 407.36 cr | 8,511.45 cr | 14,568.18 cr |
| 2024-03-31 | 11,963.25 cr | 382.01 cr | 207.17 cr | 9,575.79 cr |
| 2023-03-31 | 9,715.45 cr | 304.82 cr | 170.37 cr | 7,623.29 cr |
| 2022-03-31 | 9,147.74 cr | 302.53 cr | 873.07 cr | 6,316.31 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 3,121.29 cr | 2,384.05 cr | n/a |
| 2025-03-31 | 2,413.38 cr | 1,893.27 cr | n/a |
| 2024-03-31 | 2,152.44 cr | 1,763.23 cr | n/a |
| 2023-03-31 | 1,813.30 cr | 981.23 cr | n/a |
| 2022-03-31 | 919.78 cr | -1,425.75 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +72.63% | +9.45% | +15.39% | +10.87% | +2.53% | +0.00% |
| 2026-03-31 | +72.66% | +10.24% | +14.46% | +10.36% | +2.64% | +0.00% |
| 2025-12-31 | +72.66% | +11.34% | +13.25% | +9.30% | +2.75% | +0.00% |
| 2025-09-30 | +72.67% | +12.84% | +11.92% | +7.78% | +2.57% | +0.00% |
| 2025-06-30 | +72.68% | +13.07% | +11.50% | +7.34% | +2.75% | +0.00% |
| 2025-03-31 | +72.70% | +12.92% | +11.48% | +7.67% | +2.90% | +0.00% |
| 2024-12-31 | +72.71% | +13.34% | +11.06% | +7.83% | +2.90% | +0.00% |
| 2024-12-20 | +72.71% | +13.35% | +11.02% | +7.97% | +2.92% | +0.00% |
| 2024-09-30 | +74.87% | +12.37% | +9.90% | +6.99% | +2.86% | +0.00% |
| 2024-06-30 | +74.87% | +11.58% | +9.95% | +7.37% | +3.61% | +0.00% |
| 2024-03-31 | +74.88% | +9.87% | +11.14% | +8.57% | +4.11% | +0.00% |
| 2023-12-31 | +76.50% | +6.74% | +9.79% | +7.55% | +6.97% | +0.00% |
| 2023-09-30 | +76.50% | +4.18% | +4.56% | +3.90% | +14.76% | +0.00% |
| 2023-06-30 | +76.50% | +4.18% | +4.64% | +3.92% | +14.68% | +0.00% |
| 2023-05-04 | +76.50% | +2.61% | +2.64% | +1.83% | +18.25% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze MANKIND PHARMA with valuation, momentum and industry peers
- Compare MANKIND with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare MANKIND with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.